Greg Simon
Showing 1–3 of 3 transcripts.
- Milken Institute1h 1m
The Cancer Diagnostics Revolution | Global Conference 2024
Gregory Simon, Kara Egan, Helmy Eltoukhy, Jody Hoyos, Larry Kessler, Anaeze Offodile, Greg Simon
Experts and industry leaders convened to discuss the technological evolution of liquid biopsies for early-stage, pan-cancer detection while addressing critical barriers regarding clinical efficacy, health equity, and reimbursement. The dialogue highlighted the necessity of randomized control trials to prove mortality benefits over simple downstaging, noting that false positives can trigger invasive diagnostic odysseys without extending life. Panelists from organizations like GARDEN and Teal Health outlined specific strategic goals, including securing Medicare coverage and developing at-home screening devices to reduce the 25% of women currently behind on recommended cancer screenings.
- Milken Institute56 min
Preserving the Promise of Cancer Immunotherapy
Louise Perkins, Pablo Legorreta, Johanna Mercier, Jill O'Donnell-Tormey, Antoni Ribas, Greg Simon
The Melanoma Research Alliance, alongside the Biden Cancer Initiative and L'Oréal Paris, is addressing the persistent 50% non-response rate to current immunotherapies by promoting platform trials and data-sharing networks to eliminate redundant "Me Too" drug development. While recent clinical advances have extended survival for metastatic patients to a decade or more, experts emphasize the urgent need to de-risk academic discoveries through nonprofit incubators and standardized liquid biopsies to prevent early-stage cancer from progressing to terminal stages. Strategic recommendations from industry leaders and researchers prioritize patient-centric trial design and sustained basic science funding to ensure these breakthroughs reach community oncologists and avoid investment withdrawal from other critical therapeutic classes.
- Milken Institute1h 0m
Financing the Future of Bioscience and Pharma
Melissa Stevens, Lou DiGennaro, Rajiv Kahl, Jody Black, Matthew Perry, Greg Simon
Facing a critical funding gap where traditional venture capital and pharmaceutical giants avoid high-risk early-stage assets, diverse entities including the Leukemia & Lymphoma Society, the NIH, and crowdfunding platforms like Poliwag are deploying non-dilutive capital and democratized investment models to accelerate therapeutic development. These initiatives have successfully leveraged millions to generate billions in downstream deal flow, while regulatory shifts and public market mechanisms enable smaller biotechs to bridge the "valley of death" and reach patients faster. Ultimately, the event highlights a structural shift toward a continuum of care where government research, patient advocacy, and public markets converge to transform scientific discovery into viable treatments for life-threatening diseases.